SCHEMBL5565181

SCHEMBL5565181

CCc1ccccc1C(=O)c1sc(NCCCNS(=O)(=O)c2cc(C)ccc2OC)nc1C

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.51
POLB P06746 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PIK3CD O00329 2/20 0.45
PIK3CG P48736 1/20 0.45
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
PI4KB Q9UBF8 1/20 0.41
L3MBTL3 Q96JM7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5564428 0.89 NPY5R (0.56) NPY5RPOLBPIK3CDPIK3CGMAPT
SCHEMBL14421688 0.82 SCN1A (0.43) NPY5RSMN1; SMN2HSD17B10KDM4EALDH1A1
SCHEMBL14421756 0.79 NPY5R (0.45) NPY5RTSHRHSD17B10MAPTKMT2A
SCHEMBL5564316 0.77 NPY5R (0.55) NPY5RPOLBMAPTKDM4E
SCHEMBL5568736 0.77 NPY5R (0.61) NPY5RPOLBMAPTKDM4E
SCHEMBL5564317 0.76 NPY5R (0.54) NPY5RPOLB
SCHEMBL5568905 0.76 NPY5R (0.57) NPY5RPOLBMAPTKDM4E
SCHEMBL5570000 0.75 NPC1 (0.48) POLBSMN1; SMN2HSD17B10MAPTKMT2A
SCHEMBL5564326 0.75 NPY5R (0.59) NPY5RPOLBMAPTKDM4E
SCHEMBL5564500 0.75 LCK (0.43) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1480976-B1 THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-09-19 EP disclosed
EP-1480976-B1 THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-09-19 EP disclosed
EP-1480976-A1 THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-12-01 EP disclosed
US-6686381-B2 COMPOUNDS THAT ANTAGONIZE NEUROPEPTIDE Y AT THE Y5 RECEPTOR SUBTYPE REPRESENT AN APPROACH TO THE TREATMENT OF EATING DISORDERS SUCH AS OBESITY AND HYPERPHAGIA HOFFMANN-LA ROCHE INC. 2004-02-03 US disclosed
US-20030225141-A1 THIAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. 2003-12-04 US disclosed
WO-2003072577-A1 THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225141-A1 THIAZOLE DERIVATIVES SLC5A1, GPR119, TAS1R1 NPY5R 70/4885POLB 4868/4885SMN1; SMN2 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.